Pyxis Diagnostics is developing an AI-powered cancer diagnostics platform for predicting immuno-oncology (IO) drug response. The company's platform can predict IO drug response for many cancer types. It can also suggest alternative treatment routes in cases when the predicted drug response is low, improving the quality of life of oncological patients. Biological data collected from fresh tumor samples (using cell sorting, next-generation genetic sequencing, and proteomics), enables deep characterization of the cancer cell, different immune cells, and stromal cells. This profound analysis allows for the delineation of the cellular suppressive network (CSN) formed within the tumor microenvironment. Machine-learning algorithms can then be used for classification of responders based on differential CSN patterns. Pyxis Diagnostics aims to improve outcomes for patients and increase success rates of immunotherapies both in clinics and during the drug-development process.